Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 13/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 7/20 | 0.49 |
| ▸ | IDO1 | P14902 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6208854 | 0.88 | ITGA4 (0.57) | ITGA4ITGB1 | |
| SCHEMBL5151939 | 0.85 | ITGA4 (0.50) | ITGA4ITGB1MEN1MAPTKMT2A | |
| SCHEMBL6210735 | 0.83 | ITGA4 (0.50) | ITGA4ITGB1MEN1LMNAMAPT | |
| SCHEMBL5153516 | 0.80 | ITGA4 (0.48) | ITGA4ITGB1MEN1LMNAMAPT | |
| SCHEMBL5152799 | 0.80 | ITGA4 (0.43) | ITGA4ITGB1MEN1LMNAMAPT | |
| SCHEMBL5152442 | 0.80 | ITGA4 (0.57) | ITGA4ITGB1MEN1KMT2AGAA | |
| SCHEMBL6210969 | 0.79 | ITGA4 (0.58) | ITGA4ITGB1 | |
| SCHEMBL5151727 | 0.79 | ITGA4 (0.51) | ITGA4ITGB1MEN1LMNAMAPT | |
| SCHEMBL6212266 | 0.79 | ITGA4 (0.58) | ITGA4ITGB1LMNAMAPTKMT2A | |
| SCHEMBL6543595 | 0.79 | ITGA4 (0.56) | ITGA4ITGB1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | ITGA4 3/4885ITGB1 7/4885IDO1 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.